[1]
|
陈真云, 李晓红, 李虹, 等. O-RADS分类结合CA125、HE4及ROMA在附件肿块中的诊断效能及影响因素[J]. 现代妇产科进展, 2023, 32(4): 287-292. https://doi.org/10.13283/J.Cnki.Xdfckjz.2023.04.007
|
[2]
|
Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N. and Ducarme, G. (2019) Biomarkers and Algorithms for Diagnosis of Ovarian Cancer: CA125, HE4, RMI and ROMA, a Review. Journal of Ovarian Research, 12, Article No. 28. https://doi.org/10.1186/s13048-019-0503-7
|
[3]
|
Olsen, M., Lof, P., Stiekema, A., et al. (2021) The Diagnostic Accuracy of Human Epididymis Protein 4 (HE4) for Discriminating between Benign and Malignant Pelvic Masses: A Systematic Review and Meta-Analysis. Acta Obstetricia et Gynecologica Scandinavica, 100, 1788-1799. https://doi.org/10.1111/aogs.14224
|
[4]
|
RAdu, M.R., Pradatu, A., Duica, F., et al. (2021) Ovarian Cancer: Bio-Markers and Targeted Therapy. Biomedicines, 9, Article No. 693. https://doi.org/10.3390/biomedicines9060693
|
[5]
|
胡毓婷, 黄晓民, 缪恺, 等. 超声造影联合血清学在卵巢癌早期筛查中的应用研究[J]. 中国超声医学杂志, 2022, 38(1): 95-98. https://doi.org/10.3969/J.Issn.1002-0101.2022.01.030
|
[6]
|
邹建文, 高华. CEA、CA199、CA724和CA125在卵巢肿瘤中的诊断价值[J]. 山东医药, 2010, 50(7): 92-93.
https://doi.org/10.3969/J.Issn.1002-266X.2010.07.042
|
[7]
|
Nakagawa, N., Koda, H., Nitta, N., et al. (2015) Re-activity of CA19-9 and CA125 in Histological Subtypes of Epithelial Ovarian Tumors and Ovarian Endometriosis. Acta Medica Okayama, 69, 227-235.
|
[8]
|
Gadducci, A., Guerrieri, M. and Cosio, S. (2019) Squamous Cell Carcinoma Arising from Mature Cystic Teratoma of the Ovary: A Challenging Question for Gynecologic Oncologists. Critical Re-views in Oncology/Hematology, 133, 92-98. https://doi.org/10.1016/j.critrevonc.2018.10.005
|
[9]
|
王萍, 洪波, 郭鹏. 血清多指标联合经阴道彩超对上皮性卵巢恶性肿瘤的研究[J]. 中国超声医学杂志, 2022, 38(5): 561-565. https://doi.org/10.3969/J.Issn.1002-0101.2022.05.023
|
[10]
|
杨勇, 王冰. 人绒毛膜促性腺激素、人附睾蛋白 4、糖类抗原199联合检测对卵巢肿瘤的诊断价值[J]. 陕西医学杂志, 2019, 48(8): 1091-1093, 1101.
|
[11]
|
Zhang, R., Siu, M.K.Y., Ngan, H.Y.S. and Chan, K.K.L. (2022) Molecular Biomarkers for the Early Detection of Ovarian Cancer. International Journal of Molecular Sciences, 23, Article No. 12041.
https://doi.org/10.3390/ijms231912041
|
[12]
|
Galgano, M.T., Hampton, G.M. and Frierson, H.F. (2006) Compre-hensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. https://doi.org/10.1038/modpathol.3800612
|
[13]
|
杨玲, 周建政. 人附睾蛋白4在上皮性卵巢癌中的应用价值[J]. 临床与病理杂志, 2021, 41(3): 683-688.
https://doi.org/10.3978/J.Issn.2095-6959.2021.03.030
|
[14]
|
Zhang, C., Hu, H., Wang, X., et al. (2021) WFDC Protein: A Promising Diagnosis Biomarker of Ovarian Cancer. Journal of Cancer, 12, 5404-5412. https://doi.org/10.7150/jca.57880
|
[15]
|
Lycke, M., Ulfenborg, B., Malchau Lauesgaard, J., Kristjansdottir, B. and Sundfeldt, K. (2021) Consideration Should Be Given to Smoking, Endometriosis, Renal Function (EGFR) and Age When Interpreting CA125 and HE4 in Ovarian Tumor Diagnostics. Clinical Chemistry and Laboratory Medicine, 59, 1954-1962.
https://doi.org/10.1515/cclm-2021-0510
|
[16]
|
Drapkin, R., Von Horsten, H.H., Lin, Y., et al. (2005) Human Epi-didy-Mis Protein 4 (HE4) Is a Secreted Glycoprotein That Is Overexpressed by Serous and Endometrioid Ovarian Car-cinomas. Cancer Research, 65, 2162-2169.
https://doi.org/10.1158/0008-5472.CAN-04-3924
|
[17]
|
Behrouzi, R., Barr, C.E. and Crosbie, E.J. (2021) HE4 as a Biomarker for Endometrial Cancer. Cancers (Basel), 13, Article No. 4764. https://doi.org/10.3390/cancers13194764
|
[18]
|
中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(2021年版) [J].中国癌症杂志, 2021, 31(6): 490-500.
|
[19]
|
Zhang, L., Chen, Y. and Wang, K. (2019) Comparison of CA125, HE4, and ROMA Index for Ovarian Cancer Diagnosis. Current Problems in Cancer, 43, 135-144. https://doi.org/10.1016/j.currproblcancer.2018.06.001
|
[20]
|
Hada, A., Han, L.P., Chen, Y., et al. (2020) Compari-son of the Predictive Performance of Risk of Malignancy Indexes 1-4, HE4 and Risk of Malignancy Algorithm in the Triage of Adnexal Masses. Journal of Ovarian Research, 13, Article No. 46. https://doi.org/10.1186/s13048-020-00643-6
|
[21]
|
Kinugasa, M., Nishirnura, R., Koizumi, T., et al. (1995) Combi-nation Assay of Urinary Beta-Core Fragment of Human Chorionic Gonadotropin with Serum Tumor Markers in Gyne-cologic Cancers. Japanese Journal of Cancer Research, 86, 783-789. https://doi.org/10.1111/j.1349-7006.1995.tb02469.x
|
[22]
|
Wimalasena, J., Meehan, D., Dostal, R., Foster, J.S., Cameron, M. and Smith, M. (1993) Growth Factors Interact with Estradiol and Gonadotropins in the Regulation of Ovarian Cancer Cell Growth and Growth Factor Receptors. Oncology Research, 5, 325-337.
|
[23]
|
Kraemer, S., Jaeger, W.H. and Lang, N. (2001) Growth Regulation Effects of Gonadotropin Induced Steroidogenic Response in Human Ovarian Cancer. Anticancer Research, 21, 2005-2010.
|